PRE ORDER BodyAxis™ (CJC-1295)

Concentration: 6mg

Storage: Must be kept in a refrigerator at 2°C–8°C for optimal potency.

Status: For research purposes only

Contents: Vial, needles & autoinjector pen   

THIS ITEM IS PRE ORDER ONLY - LIMITED STOCK AVAILABLE 

Description & Mechanism

CJC‑1295 without DAC is a synthetic analogue of growth hormone–releasing hormone (GHRH 1–29) that incorporates targeted amino‑acid substitutions to improve stability compared with the native peptide. Because it lacks the drug‑affinity complex (DAC) found in conjugated versions, it displays pharmacokinetic characteristics typical of non‑conjugated GHRH analogues when used in experimental research.

In biochemical and cellular model systems, CJC‑1295 binds to and activates the GHRH receptor present on pituitary‑derived cells, triggering intracellular signalling pathways involved in endocrine regulation. Research has explored its receptor‑binding behaviour, activation kinetics, and downstream signalling responses under short‑duration exposure conditions. The molecular and physiological effects observed vary with concentration, exposure time, and experimental design, and the peptide is used primarily to study GHRH receptor signalling rather than to infer defined biological or physiological outcomes.

Applications in Research

• As a molecular tool for analysing GHRH receptor binding, activation, and signalling dynamics
• Investigation of growth hormone axis regulation and endocrine feedback pathways
• Cellular assays evaluating transcriptional responses and downstream signalling cascades
• Preclinical or clinical research models assessing extended peptide–receptor interaction associated with albumin binding

Free express shipping on all orders.